Amphiregulin Induces the Alternative Splicing of p73 Into Its Oncogenic Isoform ΔEx2p73 in Human Hepatocellular Tumors

Gastroenterology

Volumn 137, Issue 5, 2009, Pages

  Castillo, Josefa ^a   Goñi, Saioa ^a   Latasa, María Ujue ^a   Perugorría, María J ^a   Calvo, Alicia ^a   Muntané, Jordi ^b,c   Bioulac Sage, Paulette ^d,e   Balabaud, Charles ^d,f   Prieto, Jesús ^a,c   Avila, Matías A ^a   Berasain, Carmen ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

^d HÔPITAL PELLEGRIN   (France)

^e HÔPITAL SAINT ANDRÉ   (France)

^f BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA PRECURSOR; PROTEIN P73; STRESS ACTIVATED PROTEIN KINASE 1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SLU7; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ARTICLE; AUTOCRINE EFFECT; CANCER TISSUE; CARCINOMA CELL; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; PRECANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ALTERNATIVE SPLICING; CARCINOMA, HEPATOCELLULAR; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; DNA-BINDING PROTEINS; GLYCOPROTEINS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 8; NUCLEAR PROTEINS; PROTEIN ISOFORMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR SUPPRESSOR PROTEINS;

EID: 70350122931     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.07.065     Document Type: Article

References (38)

1. Stiewe T. The p53 family in differentiation and tumorigenesis. Nat Rev Cancer 7 (2007) 164-168
2. De Young M.P., and Ellisen L.W. p63 and p73 In human cancer: defining the network. Oncogene 26 (2007) 5169-5183
3. Buhlmann S., and Pützer B.M. DNp73 a matter of cancer: mechanisms and clinical implications. Biochim Biophys Acta 1785 (2008) 207-216
4. Oswald C., and Stiewe T. In good times and bad: p73 in cancer. Cell Cycle 7 (2008) 1726-1731
5. Beitzinger M., Hofmann L., Oswalds C., et al. p73 Poses a barrier to malignant transformation by limiting anchorage-independent growth. EMBO J 27 (2008) 792-803
6. Müller M., Schilling T., Sayan A.E., et al. TAp73/ΔNp73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Diff 12 (2005) 1564-1577
7. Wager M., Guilhot J., Ferrand S., et al. Prognostic value of increase in transcript levels of Tp73 Δex2-3 isoforms in low-grade glioma patients. Brit J Cancer 95 (2006) 1062-1069
8. Dominguez G., García J.M., Peña C., et al. ΔTAp73 up-regulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. J Clin Oncol 24 (2006) 805-815
9. Filippovich I., Sorokina N., Gatei M., et al. Transactivation-deficient p73α (p73Δexon2) inhibits apoptosis and competes with p53. Oncogene 20 (2001) 514-522
10. Stiewe T., Zimmermann S., Frilling A., et al. Transactivation-deficient ΔTA-p73 acts as an oncogene. Cancer Res 62 (2002) 3598-3602
11. Petrenko O., Zaika A., and Moll U.M. ΔNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo. Mol Cell Biol 23 (2003) 5540-5555
12. Stiewe T., Tuve S., Peter M., et al. Quantitative TP73 transcript analysis in hepatocellular carcinomas. Clin Cancer Res 10 (2004) 626-633
13. Tannapfel A., John K., Mise N., et al. Autonomous growth and hepatocarcinogenesis in transgenic mice overexpressing the p53 family inhibitor DNp73. Carcinogenesis 29 (2008) 211-218
14. Shin C., and Manley J.L. Cell signaling and the control of pre-mRNA splicing. Nat Rev Mol Cell Biol 5 (2004) 727-738
15. Cheng C., Yaffe M.B., and Sharp P.A. A positive feedback loop couples Ras activation and CD44 alternative splicing. Genes Dev 20 (2006) 1715-1720
16. Blaustein M., Pelisch F., and Srebrow A. Signals, pathways and splicing regulation. Int J Biochem Cell Biol 39 (2007) 2031-2048
17. Yea S., Narla G., Zhao X., et al. Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology 134 (2008) 1521-1531
18. Castillo J., Erroba E., Perugorría M.J., et al. Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res 66 (2006) 1-10
19. Desbois-Mouthon C., Cacheux M., Blivet-Van Eggelpoël V., et al. Impact of IGF-1R/EGFR crosstalks on hepatoma cell sensitivity to gefitinib. Int J Cancer 119 (2006) 2557-2566
20. Chua K., and Reed R. The RNA splicing factor hSlu7 is required for correct 3′ splice-site choice. Nature 402 (1999) 207-210
21. El-Serag A.B., and Rudolph L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132 (2007) 2557-2576
22. Berasain C., Herrero J.I., García-Trevijano E.R., et al. Expression of Wilms' tumor suppressor in the liver with cirrhosis: relation to hepatocyte nuclear factor 4 and hepatocellular function. Hepatology 38 (2003) 148-157
23. Alberstein M., Amit M., Vaknin K., et al. Regulation of transcription of the RNA splicing factor hSlu7 by Elk-1 and Sp1 affects alternative splicing. RNA 13 (2007) 1988-1999
24. Sasaki Y., Naishiro Y., Oshima Y., et al. Identification of pigment epithelium-derived factor as a direct target of the p53 family member genes. Oncogene 24 (2005) 5131-5136
25. Ishida T., Iwai A., Hijikata M., et al. The expression of phosphatidic acid phosphatase 2a, which hydrolizes lipids to generate diacylglycerol, is regulated by p73, a member of the p53 family. Biochem Biophys Res Commun 353 (2007) 74-79
26. Zheng X., and Chen X. Aquaporin 3, a glycerol and water transporter, is regulated by p73 of the p53 family. FEBS Lett 489 (2001) 4-7
27. 165b down-regulation as a marker of poor prognosis. Int J Cancer 123 (2008) 1060-1067
28. Berasain C., Castillo J., Prieto J., et al. New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system. Liver Int 27 (2007) 174-185
29. Melino G., Bernassola F., Ranalli M., et al. p73 Induces apoptosis via PUMA transactivation and bax mitochondrial translocation. J Biol Chem 279 (2004) 8076-8083
30. Bogoyevitch M.A. The isoform-specific functions of the c-Jun N-terminal kinases (JNKs): differences revealed by gene targeting. Bioessays 28 (2006) 923-934
31. Zhong S., Fromm J., and Johnson D.L. TBP is differentially regulated by c-Jun N-terminal kinase 1 (JNK1) and JNK2 through Elk-1, controlling c-Jun expression and cell proliferation. Mol Cell Biol 27 (2007) 54-64
32. Yotsumoto F., Yagi H., Suzuki S.O., et al. Validation of HB-EGF and amphiregulin as targets for human cancer therapy. Biochem Biophys Res Commun 365 (2008) 555-561
33. Pozniak C., Radinovic S., Yang A., et al. An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science 289 (2000) 304-306
34. Berasain C., García-Trevijano E.R., Castillo J., et al. Novel role for amphiregulin in protection from liver injury. J Biol Chem 280 (2005) 19012-19020
35. Schoemaker M.H., and Moshage H. Defying death: the hepatocyte's survival kit. Clin Sci 107 (2004) 13-25
36. Shomron N., Alberstein M., Reznik M., et al. Stress alters the subcellular distribution of hSlu7 and thus modulates alternative splicing. J Cell Sci 118 (2005) 1151-1159
37. Ying T., Hsieh Y., Hsieh Y., et al. Antisense oligonucleotide Elk-1 suppresses the tumorigenicity of human hepatocellular carcinoma cells. Cell Biol Int 32 (2008) 210-216
38. Pettigrew C.A., and Brown M.A. Pre-mRNA splicing aberrations and cancer. Front Biosci 13 (2008) 1090-1105